Current optimal chemotherapy for advanced urothelial cancer
暂无分享,去创建一个
[1] J. Hallenbeck,et al. A request for nondisclosure: don't tell mother. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Bajorin. The graying of testis cancer patients: what have we learned? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Manola,et al. Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) , 2007, Cancer.
[4] J. Carles,et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] D. Amadori,et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.
[6] B. Bochner,et al. Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC) , 2007 .
[7] I. Ostrovnaya,et al. A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy , 2007 .
[8] David C. Smith,et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Galsky,et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma , 2007, Investigational New Drugs.
[10] M. Galsky,et al. Phase II trial of dose‐dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function , 2007, Cancer.
[11] H. Joensuu,et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] A. Vickers,et al. Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder , 2006, Cancer.
[13] C. Obasaju,et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Thomas J. Smith,et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Raj,et al. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Crevoisier,et al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] S. Culine,et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen , 2006, British Journal of Cancer.
[18] M. Dimopoulos,et al. The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma , 2006, Cancer.
[19] B. Redman,et al. Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma , 2005, Cancer.
[20] S. Ricci,et al. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .
[21] J. Hainsworth,et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium , 2005, Cancer.
[22] L. Schumm,et al. A Phase II study of oxaliplatin in urothelial cancer. , 2005, Urologic oncology.
[23] C. Yiannoutsos,et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Ardavanis,et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study , 2005, British Journal of Cancer.
[25] A. Bamias,et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. , 2004, Urology.
[26] J. Manola,et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium , 2004, Cancer.
[27] M. Dimopoulos,et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Nicholas J Vogelzang,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.
[29] J. Manola,et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium , 2003, Cancer.
[30] J. Carles,et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract , 2003, Cancer.
[31] J. Manola,et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896) , 2002, Cancer.
[32] J. Baselga,et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine , 2002, Cancer.
[33] L. Seymour,et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. , 2002, Urologic oncology.
[34] Terry L. Smith,et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Pectasides,et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] J. Gutheil,et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Albers,et al. Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life , 2002, Oncology Research and Treatment.
[38] C. Sternberg,et al. Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy , 2001, Cancer.
[39] J. Hainsworth,et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] B. Redman,et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] I. Bodrogi,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] W. Oh,et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] H. Scher,et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract , 2000, Cancer.
[44] J. Manola,et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Mazumdar,et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] L. Crinò,et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] M. Mazumdar,et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] I. Tannock,et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] C. Sweeney,et al. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium , 1999, Cancer.
[50] J. Bacik,et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] L. Sengeløv,et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] G. Luporini,et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum , 1998 .
[53] A. Ribas,et al. Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma , 1997, Cancer.
[54] T. Kuzel,et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] I. Tannock,et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] M. Mazumdar,et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] R. Dreicer,et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] W. See,et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. , 1996, The Journal of urology.
[59] S. Mondillo,et al. Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study , 1996, Cancer.
[60] D. Neuberg,et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] F. Boccardo,et al. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial , 1994, Cancer.
[62] L. Einhorn,et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] C. Sternberg,et al. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[64] J. Gabrilove,et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] I. Tannock,et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] C. Logothetis,et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] C. Logothetis,et al. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. , 1990, Journal of the National Cancer Institute.
[68] N. Geller,et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.
[69] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[70] L. Collette,et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.
[71] S. Krege,et al. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. , 2001, The Journal of urology.